Literature DB >> 32158335

Characteristics of Advanced Colorectal Cancer Detected by Fecal Immunochemical Test Screening in Participants with a Negative Result the Previous Year.

Ryosuke Hasegawa1, Kazuo Yashima1, Yuichiro Ikebuchi1, Shuji Sasaki1, Akira Yoshida1, Koichiro Kawaguchi1, Hajime Isomoto1.   

Abstract

BACKGROUND: There is sufficient evidence to show the mortality reduction effect of colorectal cancer (CRC) screening programs using the fecal occult blood test (FOBT). However, we see cases that are found to be advanced CRC despite yearly FOBT screening.
METHODS: The aim of this study was to investigate the characteristics of advanced CRC detected by a fecal immunochemical test (FIT) screening program in participants with a negative screening result the previous year, which we call "Negative advanced CRC". A total of 109,639 participants (10.0% required colonoscopy, of whom 76.9% received one) underwent a CRC screening program using a FIT from fiscal 2009 to 2017. Negative advanced CRC was compared with advanced CRC (First advanced CRC) found at the first visit in a person who had not had a FIT screening history for more than 3 years. In addition, we compared the characteristics of Negative advanced CRC with those of interval cancer: cancer cases detected after a negative screening result and before the date of the next recommended screening.
RESULTS: A total of 339 cases of CRC (175 male: 164 female, 173 early stage: 166 advanced stage) were detected in the nine-year CRC screening period. The rate of right-sided CRCs was significantly higher in female (P < 0.01), advanced stage (P < 0.01), negative result previous year (P < 0.01), and symptom-negative (P < 0.01) participants than in each counterpart, respectively. The ratio of female (22/35; 62.9%) patients in Negative advanced CRCs tended to be high compared with that (40/83; 48.2%) in First advanced CRCs (P = 0.145). Overall, 22 (62.9%) of 35 Negative advanced CRCs and 28 (33.7%) of 83 First advanced CRCs were located in the right-sided colon, and the rate was significantly higher in Negative advanced CRCs (P < 0.01). In addition, the frequency of female patients was significantly higher in right-sided Negative advanced CRCs than in right-sided First advanced CRCs (P = 0.03).
CONCLUSION: The characteristics of Negative advanced CRC cases (female and right-sided colon) were similar to those of interval cancer reported so far. In the future, it will be necessary to introduce a screening program that is highly sensitive to right-sided CRC. ©2020 Tottori University Medical Press.

Entities:  

Keywords:  Japanese; colorectal cancer; fecal immunochemical test; interval cancer

Year:  2020        PMID: 32158335      PMCID: PMC7028528          DOI: 10.33160/yam.2020.02.009

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  39 in total

1.  The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer.

Authors:  M F Kaminski; M Bretthauer; A G Zauber; E J Kuipers; H-O Adami; M van Ballegooijen; J Regula; M van Leerdam; T Stefansson; L Påhlman; E Dekker; M A Hernán; K Garborg; G Hoff
Journal:  Endoscopy       Date:  2012-06-21       Impact factor: 10.093

Review 2.  Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.

Authors:  H W Hirai; K K F Tsoi; J Y C Chan; S H Wong; J Y L Ching; M C S Wong; J C Y Wu; F K L Chan; J J Y Sung; S C Ng
Journal:  Aliment Pharmacol Ther       Date:  2016-02-09       Impact factor: 8.171

3.  Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.

Authors:  Manon van der Vlugt; Esmée J Grobbee; Patrick M M Bossuyt; Amanda Bos; Evelien Bongers; Wolfert Spijker; Ernst J Kuipers; Iris Lansdorp-Vogelaar; Manon C W Spaander; Evelien Dekker
Journal:  Gastroenterology       Date:  2017-05-05       Impact factor: 22.682

4.  Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program.

Authors:  Stephen R Cole; Graeme R Tucker; Joanne M Osborne; Susan E Byrne; Peter A Bampton; Robert J L Fraser; Graeme P Young
Journal:  Med J Aust       Date:  2013-04-01       Impact factor: 7.738

5.  Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.

Authors:  Leo G M van Rossum; Anne F van Rijn; Andre L M Verbeek; Martijn G H van Oijen; Robert J F Laheij; Paul Fockens; Jan B M J Jansen; Eddy M M Adang; Evelien Dekker
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

6.  Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme.

Authors:  M D Gill; M G Bramble; C J Rees; T J W Lee; D M Bradburn; S J Mills
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

7.  The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study.

Authors:  G Libby; D H Brewster; P L McClements; F A Carey; R J Black; J Birrell; C G Fraser; R J C Steele
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

8.  Influence of stage at diagnosis on survival differences for rectal cancer in three European populations.

Authors:  E Monnet; J Faivre; L Raymond; I Garau
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

9.  Vital signs: colorectal cancer screening test use--United States, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-08       Impact factor: 17.586

10.  Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers.

Authors:  M D Gill; M G Bramble; M A Hull; S J Mills; E Morris; D M Bradburn; Y Bury; C E Parker; T J W Lee; C J Rees
Journal:  Br J Cancer       Date:  2014-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.